Cytotoxic therapy

Details Cytotoxic therapy Cytotoxic therapy

A - Human Necessities

61

K

167/100, 167/129

A61K 47/48 (2006.01) A61K 39/44 (2006.01) A61K 51/08 (2006.01)

Patent

CA 1329119

Abstract of the Disclosure Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoistic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agens can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy.

594582

Affiliated with

Also associated with

Rating

Cytotoxic therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytotoxic therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1307770